About APIM Therapeutics
APIM Therapeutics is a company based in Trondheim (Norway) founded in 2009. APIM Therapeutics has raised $3.56 million across 5 funding rounds from investors including Berg Capital Group, Investinor and Sarsia Seed. The company has 1 employees as of December 31, 2021. APIM Therapeutics offers products and services including ATX-101 and Peptide Drugs Pipeline. APIM Therapeutics operates in a competitive market with competitors including TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
- Headquarter Trondheim, Norway
- Employees 1 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apim Therapeutics As
-
Annual Revenue
$10.86 K (USD)0as on Dec 31, 2022
-
Net Profit
-$2.75 M (USD)-78as on Dec 31, 2022
-
EBITDA
-$2.75 M (USD)-78as on Dec 31, 2022
-
Total Equity Funding
$3.56 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Berg Capital Group
& 4 more
-
Employee Count
1
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of APIM Therapeutics
APIM Therapeutics offers a comprehensive portfolio of products and services, including ATX-101 and Peptide Drugs Pipeline.
Peptide drug targeting stress responses in cancer cells for treatment.
Pipeline of drugs addressing cancer stress responses in clinical settings.
People of APIM Therapeutics
Unlock access to complete
Unlock access to complete
Board Team
6 people
Leadership Team
2 people
Finance and Accounting
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of APIM Therapeutics
APIM Therapeutics has successfully raised a total of $3.56M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in APIM Therapeutics
APIM Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Berg Capital Group, Investinor and Sarsia Seed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for APIM Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by APIM Therapeutics
Investment portfolio details for APIM Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - APIM Therapeutics
Detailed financials for APIM Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apim Therapeutics Comparisons
Peer comparison for APIM Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of APIM Therapeutics
APIM Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Lyell Immunopharma, Hummingbird Bioscience, GigaGen and Candel Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
Viral immunotherapies are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
Detailed competitors of APIM Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apim Therapeutics
Complete news archive for APIM Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about APIM Therapeutics
APIM Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
APIM Therapeutics is headquartered in Trondheim, Norway. It is registered at Trondheim, Trøndelag, Norway.
APIM Therapeutics is a funded company, having raised a total of $3.56M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at APIM Therapeutics is 1.
Annual revenue of APIM Therapeutics is $10.86K as on Dec 31, 2022.
APIM Therapeutics was founded in 2009 in Trondheim, Norway, within the biotechnology sector. Anti-cancer therapies are developed to potentiate chemotherapy-induced responses in cancer cells through a pipeline of peptide drugs. These target PCNA-dependent stress responses, with PCNA serving as a regulator of DNA replication, repair, and cell cycle control. The flagship candidate, ATX-101, has demonstrated proof-of-concept in animal models for blood and solid tumors.
APIM Therapeutics's top competitors include Hummingbird Bioscience, Lyell Immunopharma and GigaGen.
APIM Therapeutics offers ATX-101 and Peptide Drugs Pipeline.
APIM Therapeutics has 5 investors. Key investors include Berg Capital Group, Investinor, Sarsia Seed, Televenture, and Birk Venture.